| Year |
Citation |
Score |
| 2023 |
Guerlavais V, Sawyer TK, Carvajal L, Chang YS, Graves B, Ren JG, Sutton D, Olson KA, Packman K, Darlak K, Elkin C, Feyfant E, Kesavan K, Gangurde P, Vassilev LT, et al. Discovery of Sulanemadlin (ALRN-6924), the First Cell-Permeating, Stabilized α-Helical Peptide in Clinical Development. Journal of Medicinal Chemistry. PMID 37439511 DOI: 10.1021/acs.jmedchem.3c00623 |
0.343 |
|
| 2021 |
Zhou X, Singh M, Sanz Santos G, Guerlavais V, Carvajal LA, Aivado M, Zhan Y, Oliveira MMS, Westerberg LS, Annis DA, Johnsen JI, Selivanova G. Pharmacological activation of p53 triggers viral mimicry response thereby abolishing tumor immune evasion and promoting anti-tumor immunity. Cancer Discovery. PMID 34230007 DOI: 10.1158/2159-8290.CD-20-1741 |
0.471 |
|
| 2018 |
Carvajal LA, Neriah DB, Senecal A, Benard L, Thiruthuvanathan V, Yatsenko T, Narayanagari SR, Wheat JC, Todorova TI, Mitchell K, Kenworthy C, Guerlavais V, Annis DA, Bartholdy B, Will B, et al. Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia. Science Translational Medicine. 10. PMID 29643228 DOI: 10.1126/Scitranslmed.Aao3003 |
0.493 |
|
| 2017 |
Antony-Debré I, Paul A, Leite J, Mitchell K, Kim HM, Carvajal LA, Todorova TI, Huang K, Kumar A, Farahat AA, Bartholdy B, Narayanagari SR, Chen J, Ambesi-Impiombato A, Ferrando AA, et al. Pharmacological inhibition of the transcription factor PU.1 in leukemia. The Journal of Clinical Investigation. PMID 29083320 DOI: 10.1172/Jci92504 |
0.304 |
|
| 2016 |
Carvajal LA, Steidl U. Eliminating Cancer Stem Cells in CML with Combination Transcriptional Therapy. Cell Stem Cell. 19: 6-8. PMID 27392220 DOI: 10.1016/J.Stem.2016.06.005 |
0.315 |
|
| 2015 |
Will B, Vogler TO, Narayanagari S, Bartholdy B, Todorova TI, da Silva Ferreira M, Chen J, Yu Y, Mayer J, Barreyro L, Carvajal L, Neriah DB, Roth M, van Oers J, Schaetzlein S, et al. Minimal PU.1 reduction induces a preleukemic state and promotes development of acute myeloid leukemia. Nature Medicine. PMID 26343801 DOI: 10.1038/Nm.3936 |
0.323 |
|
| 2015 |
Lukin DJ, Carvajal LA, Liu WJ, Resnick-Silverman L, Manfredi JJ. p53 Promotes cell survival due to the reversibility of its cell-cycle checkpoints. Molecular Cancer Research : McR. 13: 16-28. PMID 25158956 DOI: 10.1158/1541-7786.Mcr-14-0177 |
0.751 |
|
| 2013 |
Hamard PJ, Barthelery N, Hogstad B, Mungamuri SK, Tonnessen CA, Carvajal LA, Senturk E, Gillespie V, Aaronson SA, Merad M, Manfredi JJ. The C terminus of p53 regulates gene expression by multiple mechanisms in a target- and tissue-specific manner in vivo. Genes & Development. 27: 1868-85. PMID 24013501 DOI: 10.1101/Gad.224386.113 |
0.565 |
|
| 2013 |
Carvajal LA, Manfredi JJ. Another fork in the road--life or death decisions by the tumour suppressor p53. Embo Reports. 14: 414-21. PMID 23588418 DOI: 10.1038/Embor.2013.25 |
0.771 |
|
| 2012 |
Carvajal LA, Hamard PJ, Tonnessen C, Manfredi JJ. E2F7, a novel target, is up-regulated by p53 and mediates DNA damage-dependent transcriptional repression. Genes & Development. 26: 1533-45. PMID 22802528 DOI: 10.1101/Gad.184911.111 |
0.577 |
|
| Show low-probability matches. |